Cyclerion Therapeutics Inc (NASDAQ:CYCN) — Market Cap & Net Worth
Market Cap & Net Worth: Cyclerion Therapeutics Inc (CYCN)
Cyclerion Therapeutics Inc (NASDAQ:CYCN) has a market capitalization of $12.51 Million ($12.51 Million) as of May 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #26303 globally and #5260 in its home market, demonstrating a 10.51% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Cyclerion Therapeutics Inc's stock price $3.26 by its total outstanding shares 4330314 (4.33 Million). Analyse Cyclerion Therapeutics Inc (CYCN) cash flow conversion to see how efficiently the company converts income to cash.
Cyclerion Therapeutics Inc Market Cap History: 2019 to 2026
Cyclerion Therapeutics Inc's market capitalization history from 2019 to 2026. Data shows change from $235.57 Million to $14.12 Million (-45.61% CAGR).
Index Memberships
Cyclerion Therapeutics Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.41 Trillion | 0.00% | #755 of 976 |
|
NASDAQ Composite
IXIC
|
$38.77 Trillion | 0.00% | #2483 of 3165 |
Weight: Cyclerion Therapeutics Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Cyclerion Therapeutics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Cyclerion Therapeutics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
2.65x
Cyclerion Therapeutics Inc's market cap is 2.65 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2019 | $235.57 Million | $4.51 Million | -$123.01 Million | 52.27x | N/A |
| 2020 | $265.02 Million | $2.30 Million | -$77.80 Million | 115.42x | N/A |
| 2021 | $148.96 Million | $3.32 Million | -$51.65 Million | 44.87x | N/A |
| 2022 | $56.83 Million | $297.00K | -$44.08 Million | 191.35x | N/A |
| 2024 | $13.94 Million | $2.00 Million | -$3.06 Million | 6.97x | N/A |
| 2025 | $5.50 Million | $2.07 Million | -$3.53 Million | 2.65x | N/A |
Competitor Companies of CYCN by Market Capitalization
Companies near Cyclerion Therapeutics Inc in the global market cap rankings as of May 4, 2026.
Key companies related to Cyclerion Therapeutics Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Cyclerion Therapeutics Inc Historical Marketcap From 2019 to 2026
Between 2019 and today, Cyclerion Therapeutics Inc's market cap moved from $235.57 Million to $ 14.12 Million, with a yearly change of -45.61%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $14.12 Million | +156.69% |
| 2025 | $5.50 Million | -60.56% |
| 2024 | $13.94 Million | -3.88% |
| 2023 | $14.51 Million | -74.47% |
| 2022 | $56.83 Million | -61.85% |
| 2021 | $148.96 Million | -43.79% |
| 2020 | $265.02 Million | +12.50% |
| 2019 | $235.57 Million | -- |
End of Day Market Cap According to Different Sources
On May 4th, 2026 the market cap of Cyclerion Therapeutics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $12.51 Million USD |
| MoneyControl | $12.51 Million USD |
| MarketWatch | $12.51 Million USD |
| marketcap.company | $12.51 Million USD |
| Reuters | $12.51 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Cyclerion Therapeutics Inc
Cyclerion Therapeutics, Inc., a biopharmaceutical company, develops treatments for serious diseases serious diseases with novel sGC stimulators in both the central nervous system (CNS) and the periphery. It is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to treat cardiovascular diseases; and Praliciguat, a sy… Read more